Literature DB >> 19661212

In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

Jelena Tojcic1, Marie-Odile Benoit-Biancamano, Michael H Court, Robert J Straka, Patrick Caron, Chantal Guillemette.   

Abstract

Fenofibric acid (FA), the active moiety of fenofibrate, is an agonist of the peroxisome proliferator-activated nuclear receptor alpha that modulates triglyceride and cholesterol profiles. Lipid response to fenofibrate and FA serum concentrations is highly variable. Although FA is reported to be almost exclusively inactivated by UDP-glucuronosyltransferases (UGTs) into FA-glucuronide (FA-G), the contribution of UGT isoenzymes has never been systematically assessed. Heterologously expressed human UGT1A and UGT2B and their coding variants were tested for FA glucuronidation using liquid chromatography/mass spectrometry. Recombinant UGT2B7 presented the highest V(max)/K(m) value (2.10 microl/min/mg), 16-fold higher than the activity of other reactive UGTs, namely, UGT1A3, UGT1A6, and UGT1A9 (0.13, 0.09, and 0.02 microl/min/mg, respectively). UGT2B7.1 (His(268)) and UGT2B7.2 (Tyr(268)) enzyme activity was similar, whereas UGT1A3.2 (R(11)A(47)), UGT1A3.3 (Trp(11)), and UGT1A9.3 (Thr(33)) showed 61 to 96% reduced V(max)/K(m) values compared with the respective (1) reference proteins. FA-G formation by a human liver bank (n = 48) varied by 10-fold, but the rate of formation was not associated with common genetic variations in UGT1A3, UGT1A6, UGT1A9, and UGT2B7. Correlation with activities for the probe substrates zidovudine (UGT2B7; r(2) = 0.75), mycophenolic acid (UGT1A9; r(2) = 0.42), fulvestrant (UGT1A3; r(2) = 0.36), but not serotonin (UGT1A6; r(2) = 0.06) indicated a primary role for UGT2B7 and lesser roles of UGT1A9 and UGT1A3 in hepatic FA glucuronidation. This was confirmed by a strong correlation of FA-G formation with UGT2B7 protein content and inhibition by fluconazole, a known UGT2B7 selective inhibitor. Additional studies are required to identify genetic factors contributing to the observed FA glucuronidation variability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19661212      PMCID: PMC2774983          DOI: 10.1124/dmd.109.029058

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

Review 1.  Update on fenofibrate.

Authors:  David R P Guay
Journal:  Cardiovasc Drug Rev       Date:  2002

2.  Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

Authors:  F Innocenti; L Iyer; J Ramírez; M D Green; M J Ratain
Journal:  Drug Metab Dispos       Date:  2001-05       Impact factor: 3.922

3.  Effects of fibrates on metabolism of statins in human hepatocytes.

Authors:  Thomayant Prueksaritanont; Cuyue Tang; Yue Qiu; Lillian Mu; Raju Subramanian; Jiunn H Lin
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

4.  Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.

Authors:  C R Bhasker; W McKinnon; A Stone; A C Lo; T Kubota; T Ishizaki; J O Miners
Journal:  Pharmacogenetics       Date:  2000-11

5.  Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).

Authors:  J W Lampe; J Bigler; A C Bush; J D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-03       Impact factor: 4.254

6.  A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.

Authors:  Yannick Duguay; Cecilie Báár; Frank Skorpen; Chantal Guillemette
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

7.  Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.

Authors:  Lyne Villeneuve; Hugo Girard; Louis-Charles Fortier; Jean-Francois Gagné; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2003-08-27       Impact factor: 4.030

8.  Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.

Authors:  Vincent Ménard; Hugo Girard; Mario Harvey; Louis Pérusse; Chantal Guillemette
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

9.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.

Authors:  Michael H Court; Soundarajan Krishnaswamy; Qin Hao; Su X Duan; Christopher J Patten; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

10.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

Authors:  Jean-François Gagné; Valerie Montminy; Patrick Belanger; Kim Journault; Genevieve Gaucher; Chantal Guillemette
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

View more
  6 in total

1.  Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.

Authors:  Lori A Gordon; Christine Y Malati; Colleen Hadigan; Mary McLaughlin; Raul M Alfaro; Mónica M Calderón; Joseph A Kovacs; Scott R Penzak
Journal:  Pharmacotherapy       Date:  2016-01       Impact factor: 4.705

Review 2.  Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.

Authors:  Stella Aslibekyan; Robert J Straka; Marguerite R Irvin; Steven A Claas; Donna K Arnett
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-03

Review 3.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

4.  Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

Authors:  Sumit Parmar; Julia Carolin Stingl; Ariana Huber-Wechselberger; Alexander Kainz; Wilfried Renner; Uwe Langsenlehner; Peter Krippl; Jürgen Brockmöller; Elisabeth Haschke-Becher
Journal:  Breast Cancer Res       Date:  2011-06-09       Impact factor: 6.466

5.  Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.

Authors:  Guofei Li; Mingming Zhao; Feng Qiu; Yaxin Sun; Limei Zhao
Journal:  Drug Des Devel Ther       Date:  2018-12-20       Impact factor: 4.162

Review 6.  Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies.

Authors:  Magda Dubińska-Magiera; Marta Migocka-Patrzałek; Damian Lewandowski; Małgorzata Daczewska; Krzysztof Jagla
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.